Immutep Reaches 50% Enrolment in Global Phase III Lung Cancer Trial
at www.tipranks.com (Tue, 10-Feb 6:33 AM)
Immutep Accelerates Phase III TACTI-004 Trial, Enrolling Over 38% of Patients and Securing Approvals Across 27 Countries
Market Chameleon (Wed, 17-Dec 11:48 AM)
Immutep’s $349.5 Million Milestone Collaboration with Dr. Reddy’s Signals Strong Global Ambitions for Oncology Drug Eftilagimod Alfa
Market Chameleon (Mon, 8-Dec 10:30 AM)
